Skip to main content
SpringerLink
Log in
Book cover

Antiphospholipid Syndrome pp 117–132Cite as

Task Force Report on “Criteria” Antiphospholipid Antibody Tests

  • Chapter
  • First Online:

  • 631 Accesses

Abstract

A Task Force of experts in the Antiphospholipid Syndrome (APS) field met prior to the 13th International Congress on Antiphospholipid Antibodies and addressed a number of critical questions regarding the antiphospholipid antibody (aPL) tests included in current international consensus criteria for the classification of APS (anticardiolipin antibodies (aCL), anti-β2glycoprotein I antibodies (aβ2GPI), and lupus anticoagulant (LA) test, namely, the “criteria” aPL tests). The Task Force was divided into the following three subgroups: (1) aCL and aβ2GPI tests, (2) LA test, and (3) the role of aPL as thrombotic risk factors. Subgroup 1 reviewed and critiqued the current state of aCL/aβ2GPI testing and recommended developing international consensus guidelines for performance of these assays and establishing universal units of measurement for anti-β2GPI. Subgroup 2 reviewed recent guidelines for LA testing published by the International Society of Thrombosis and Haemostasis Standardization Subcommittee (ISTH-SSC) on Lupus Anticoagulants and Phospholipid-dependent Antibodies; the subgroup recommended continued close collaboration with ISTH-SSC to address remaining issues, including the role of TCT and PT in LA testing and the validity of integrated test systems that lack mixing studies. Subgroup 3 emphasized the need for more data on the risks associated with aPL and recommended collaborative studies using existing large, population-based, prospective cohorts with available data on thrombosis and/or pregnancy outcomes. Such studies should include a comprehensive panel of current and newer aPL assays, assess the effect of antibody titer, analyze the risks associated with combinations of aPL, and use state-of-the-art statistical approaches for assessment of risk factors.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–11.

    Article  PubMed  CAS  Google Scholar 

  2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  PubMed  CAS  Google Scholar 

  3. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol. 2002;118:548–57.

    Article  PubMed  Google Scholar 

  4. Reber G, Schousboe I, Tincani A, et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost. 2002;88:66–73.

    PubMed  CAS  Google Scholar 

  5. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anti-cardiolipin test: report of an international workshop held 4 April 1986. Clin Exp Immunol. 1987;68:215–22.

    PubMed Central  PubMed  CAS  Google Scholar 

  6. Harris EN. Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol. 1990;94:476–84.

    PubMed  CAS  Google Scholar 

  7. Harris EN, Pierangeli S, Birch D. Anticardiolipin wet workshop report. Fifth international symposium on antiphospholipid antibodies. Am J Clin Pathol. 1994;101:616–24.

    PubMed  CAS  Google Scholar 

  8. Pierangeli SS, Stewart M, Silva LK, Harris EN. An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies. J Rheumatol. 1998;25:156–60.

    PubMed  CAS  Google Scholar 

  9. Reber G, Arvieux J, Comby E, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d’Etudes sur l’Hemostase et la Thrombose). Thromb Haemost. 1995;73:444–52.

    PubMed  CAS  Google Scholar 

  10. Wong R, Wilson R, Pollock W, Steele R, Gillis D. Anti-cardiolipin antibody testing and reporting practices among laboratories participating in a large external Quality Assurance Program. Pathology. 2004;36:174–81.

    Article  PubMed  Google Scholar 

  11. Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations—a cooperative project of the European Antiphospholipid Forum. Thromb Haemost. 2001;86:575–83.

    PubMed  CAS  Google Scholar 

  12. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus. 2002;11:269–75.

    Article  PubMed  CAS  Google Scholar 

  13. Kutteh WH, Franklin RD. Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centers. Am J Obstet Gynecol. 2004;191:440–8.

    Article  PubMed  CAS  Google Scholar 

  14. Wong R, Favaloro E, Pollock W, et al. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays. Pathology. 2004;36:182–92.

    Article  PubMed  CAS  Google Scholar 

  15. Goudemand J, Caron C, De PD, et al. Evaluation of sensitivity and specificity of a standardized procedure using different reagents for the detection of lupus anticoagulants. The Working Group on Hemostasis of the Societe Francaise de Biologie Clinique and for the Groupe d’Etudes sur I’Hemostase et la Thrombose. Thromb Haemost. 1997;77:336–42.

    PubMed  CAS  Google Scholar 

  16. Exner T, Triplett DA, Taberner DA, Howard MA, Harris EN. Comparison of test methods for the lupus anticoagulant: international survey on lupus anticoagulants-I (ISLA-1). Thromb Haemost. 1990;64:478–84.

    PubMed  CAS  Google Scholar 

  17. Laboratory heterogeneity of the lupus anticoagulant: a multicentre study using different clotting assays on a panel of 78 samples. Hemostasis Committee of the “Societe Francaise de Biologie Clinique”. Thromb Res 1992;66:349–64.

    Google Scholar 

  18. Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France. Working Group on Hemostasis of the Societe Francaise de Biologie Clinique. Thromb Haemost 1993;70:781–6.

    Google Scholar 

  19. Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost. 1997;77:934–7.

    PubMed  CAS  Google Scholar 

  20. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoproteinI. Thromb Haemost. 1999;81:929–34.

    PubMed  CAS  Google Scholar 

  21. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost. 2004;2:1860–2.

    Article  PubMed  CAS  Google Scholar 

  22. Pierangeli SS, Harris EN. A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is? Semin Thromb Hemost. 2008;34:313–28.

    Article  PubMed  CAS  Google Scholar 

  23. The Lupus Anticoagulant Working Party. Detection of lupus like anticoagulant: current laboratory practice in the United Kingdom. J Clin Pathol. 1990;43:73–5.

    Article  Google Scholar 

  24. Guidelines on testing for the lupus anticoagulant. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol. 1991;44:885–9.

    Article  Google Scholar 

  25. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost. 1991;65:320–2.

    PubMed  CAS  Google Scholar 

  26. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185–90.

    PubMed  CAS  Google Scholar 

  27. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737–40.

    Article  PubMed  CAS  Google Scholar 

  28. Favaloro EJ, Wong RC. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost. 2008;34:389–410.

    Article  PubMed  CAS  Google Scholar 

  29. Favaloro EJ, Silvestrini R, Mohammed A. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach. Pathology. 1999;31:142–7.

    Article  PubMed  CAS  Google Scholar 

  30. Erkan D, Derksen WJ, Kaplan V, et al. Real world experience with antiphospholipid antibody tests: how stable are results over time? Ann Rheum Dis. 2005;64:1321–5.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  31. Peaceman AM, Silver RK, MacGregor SN, Socol ML. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol. 1992;166:1780–7.

    Article  PubMed  CAS  Google Scholar 

  32. Pierangeli SS, Gharavi AE, Harris EN. Testing for antiphospholipid antibodies: problems and solutions. Clin Obstet Gynecol. 2001;44:48–57.

    Article  PubMed  CAS  Google Scholar 

  33. Pierangeli SS, De Groot PG, Dlott J, et al. ‘Criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus. 2011;20:182–90.

    Article  PubMed  CAS  Google Scholar 

  34. Budd R, Harley E, Quarshie A, Henderson V, Harris EN, Pierangeli SS. A re-appraisal of the normal cut-off assignment for anticardiolipin IgM tests. J Thromb Haemost. 2006;4:2210–4.

    Article  PubMed  CAS  Google Scholar 

  35. Ruffatti A, Olivieri S, Tonello M, et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost. 2008;6:1693–6.

    Article  PubMed  CAS  Google Scholar 

  36. Roubey RA. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. Lupus. 2010;19:440–5.

    Article  PubMed  CAS  Google Scholar 

  37. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117:997–1002.

    Article  PubMed  CAS  Google Scholar 

  38. Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol. 2002;119:1005–10.

    Article  PubMed  CAS  Google Scholar 

  39. Naess IA, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost. 2006;4:44–9.

    Article  PubMed  CAS  Google Scholar 

  40. De Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005;3:1993–7.

    Article  PubMed  Google Scholar 

  41. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, De Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8:998–1005.

    Article  PubMed  CAS  Google Scholar 

  42. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93:1147–52.

    PubMed  CAS  Google Scholar 

  43. Pengo V, Biasiolo A, Gresele P, et al. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol. 2007;27:e309–10.

    Article  PubMed  CAS  Google Scholar 

  44. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827–32.

    Article  PubMed  CAS  Google Scholar 

  45. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237–42.

    Article  PubMed  CAS  Google Scholar 

  46. Pengo V, Biasiolo A, Rampazzo P, Brocco T. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost. 1999;81:256–8.

    PubMed  CAS  Google Scholar 

  47. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118:4714–8.

    Google Scholar 

  48. Otomo K, Atsumi T, Amengual O, et al. The efficacy of antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504–12.

    Article  PubMed  CAS  Google Scholar 

  49. Pierangeli SS, Harris EN. A protocol for determination of anticardiolipin antibodies by ELISA. Nat Protoc. 2008;3:840–8.

    Article  PubMed  CAS  Google Scholar 

  50. Wong RC, Gillis D, Adelstein S, et al. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology. 2004;36:63–8.

    Article  PubMed  CAS  Google Scholar 

  51. Wong RC, Favaloro EJ. A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays. Semin Thromb Hemost. 2008;34:361–72.

    Article  PubMed  CAS  Google Scholar 

  52. Wong RC, Favaloro EJ, Adelstein S, et al. Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting. Pathology. 2008;40:58–63.

    Article  PubMed  CAS  Google Scholar 

  53. Reber G, de Moerloose P. Anti-beta2-glycoprotein I antibodies—when and how should they be measured? Thromb Res. 2004;114:527–31.

    Article  PubMed  CAS  Google Scholar 

  54. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol. 2000;109:704–15.

    Article  PubMed  CAS  Google Scholar 

  55. Wong RC, Adelstein S, Gillis D, Favaloro EJ. Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing. Semin Thromb Hemost. 2005;31:39–48.

    Article  PubMed  Google Scholar 

  56. Tincani A, Allegri F, Balestrieri G, et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res. 2004;114:553–8.

    Article  PubMed  CAS  Google Scholar 

  57. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990;336:177–8.

    Article  PubMed  CAS  Google Scholar 

  58. Lakos G, Favaloro EJ, Harris EN, et al. International consensus guidelines on anticardiolipin and anti-beta(2) glycoprotein I testing: A report from the APL task force at the 13(th) international congress on antiphospholipid antibodies. Arthritis Rheum 2011 Sep 27. doi: 10.1002/art.33349 [Epub ahead of print]. 2012;64:1–10.

    Google Scholar 

  59. Ichikawa K, Tsutsumi A, Atsumi T, et al. A chimeric antibody with the human γ1 constant region as a putative standard for assays to detect IgG β2-glycoprotein I-dependent anticardiolipin and anti- β2-glycoprotein I antibodies. Arthritis Rheum. 1999;42:2461–70.

    Article  PubMed  CAS  Google Scholar 

  60. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–10.

    Article  PubMed  CAS  Google Scholar 

  61. Recommendations for the preparation, characterization and establishment of international and other biological reference standards (revised 2004). World Health Organization WHO Technical Report Series 2006; No. 932.

    Google Scholar 

  62. Pierangeli S, Favaloro EJ, Lakos G, et al. Standards and reference materials for the anticardiolipin and anti-b2glycoprotein I assays: a report of recommendations from the APL task force at the 13th international congress on antiphospholipid antibodies. Clin Chim Acta. 2012;413:358–60.

    Article  PubMed  CAS  Google Scholar 

  63. Lewis S, Keil LB, Binder WL, DeBari VA. Standardized measurement of major immunoglobulin class (IgG, IgA, and IgM) antibodies to β2-glycoprotein I in patients with antiphospholipid syndrome. J Clin Lab Anal. 1998;12:293–7.

    Article  PubMed  CAS  Google Scholar 

  64. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408–16.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

In addition to the authors, the members of the Task Force on Criteria Antiphospholipid Antibody Tests” include the following: Phillip G. de Groot, PhD (University Medical Center, Utrecht, The Netherlands), Jeffrey Dlott, MD (Quest Diagnostics Laboratories, Chantilly, VA, USA), Emmanuel Favaloro, PhD (Westmead Hospital,Westmead, NSW, Australia), E. Nigel Harris, MD (University of the West Indies. Office of the Vice Chancellor. University of the West Indies. Kingston, Jamaica, WI), Gabriella Lakos, MD, PhD (INOVA Diagnostics Inc. San Diego, CA) Pier Luigi Meroni, MD (Ist G. Pini and Istituto Auxologico Italiano, Milan, Italy), Thomas Ortel, MD (Duke University Medical Center, Durham, NC, USA), Kotaro Otomo, MD (Hokkaido University Graduate School of Medicine, Sapporo, Japan); Vittorio Pengo, MD (University of Padova, Padova, Italy), Angela Tincani, MD (Universty of Brescia, Italy), and Richard Wong, MD (Royal Brisbane and Women’s Hospital, Queensland, Australia). Conflict of InterestSilvia Pierangeli and E. Nigel Harris are co-owners of Louisville APL Diagnostics, Inc. Gabriella Lakos is an employee of INOVA Diagnostics Inc.

Author information

Authors and Affiliations

  1. Department of Medicine and Thurston Arthritis Research Center, The University of North Carolina at Chapel Hill, CB #7280, Rm. 3330 Thurston Bldg., Chapel Hill, NC, 27599-7280, USA

    Robert A. S. Roubey MD

  2. Division of Rheumatology, Department of Internal Medicine, Microbiology and Pathology, University of Texas Medical Branch, Galveston, TX, USA

    Silvia S. Pierangeli PhD

Authors
  1. Robert A. S. Roubey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvia S. Pierangeli PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert A. S. Roubey MD .

Editor information

Editors and Affiliations

  1. The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, USA

    Doruk Erkan

  2. University of Texas Medical Branch, 301 University Boulevard, Galveston, 77555-0883, Texas, USA

    Silvia S. Pierangeli

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Roubey, R.A.S., Pierangeli, S.S. (2012). Task Force Report on “Criteria” Antiphospholipid Antibody Tests. In: Erkan, D., Pierangeli, S. (eds) Antiphospholipid Syndrome. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-3194-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3194-7_7

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-3193-0

  • Online ISBN: 978-1-4614-3194-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation